Acupoint Photodynamic Therapy and Traditional Chinese Medicine to be evaluated for improving Diminished Ovarian Reserve

<b>Diminished Ovarian Reserve (DOR)</b>, characterized by reduced recruitable follicles and declining oocyte quality, significantly impacts female fertility and can lead to early menopause. Current medical interventions to prevent or reverse ovarian damage, particularly from factors like cancer treatments, are largely unsatisfactory. This gap highlights an urgent need for novel therapeutic strategies that can preserve or enhance ovarian function, offering hope for improved reproductive and long-term health outcomes for affected women.

This single-center, prospective, parallel, randomized, controlled clinical trial is recruiting patients with <b>Diminished Ovarian Reserve (DOR)</b>. Participants will be randomly assigned to one of three groups for a 3-month treatment period: <b>LLLT</b> (acupoint photodynamic therapy) + placebo (Dingkun Dan Simulant), <b>LLLT</b> (acupoint photodynamic therapy) + <b>Chinese medicine (Dingkun Dan)</b>, or <b>Chinese medicine (Dingkun Dan)</b> alone. Clinical data and serum metabolomics will be assessed at baseline and after the 3-month intervention. Secondary outcomes include the number and quality of oocytes retrieved at OPU and embryo quality after IVF.

This is a recruiting clinical trial, and no results are available yet. The study is designed to systematically collect and analyze clinical data, including the number of oocytes retrieved at OPU, oocyte quality, and the number and quality of embryos at the end of IVF treatment. Additionally, serum metabolomics will be assessed to identify potential biomarkers and mechanistic insights into how acupoint photodynamic therapy and traditional Chinese medicine might influence ovarian reserve. Specific findings regarding these outcomes are pending completion of the trial and data analysis.